DexCom (DXCM) Misses Q1 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts DXCM Hot Sheet
Price: $88.48 +6.64%
Financial Fact:
Development grant and other revenue: 0
Today's EPS Names:
ARIS, COHR, ATS, More
Financial Fact:
Development grant and other revenue: 0
Today's EPS Names:
ARIS, COHR, ATS, More
Join SI Premium – FREE
DexCom (NASDAQ: DXCM) reported Q1 EPS of $0.32, $0.20 worse than the analyst estimate of $0.52. Revenue for the quarter came in at $628.8 million versus the consensus estimate of $624.47 million.
GUIDANCE:
DexCom sees FY2022 revenue of $2.82-2.92 billion, versus the consensus of $2.92 billion.
- Non-GAAP Gross Profit Margin of approximately 65%
- Non-GAAP Operating Margin of approximately 16%
- Adjusted EBITDA Margin of approximately 25%
For earnings history and earnings-related data on DexCom (DXCM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Veracyte (VCYT) Tops Q3 EPS by 10c ; Offers Guidance
- Myriad Genetics (MYGN) Tops Q3 EPS by 9c ; Offers Guidance
- National Fuel Gas (NFG) Tops Q4 EPS by 18c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
